Graphite Bio Profit Margin

Graphite Bio (GRPH) currently reports a profit margin of -1134.97% as of September 2026. That compares with -467.36% in the prior-year period — down 142.8% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore Graphite Bio's profit margin history and peer comparisons.

Graphite Bio's profit margin decreased from -467.36% to -1134.97% — a 142.8% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Graphite Bio's profit margin of -1134.97% is lower than the Healthcare sector average of 19.13%. That is roughly 6032.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Graphite Bio's current -1134.97% should be judged against Healthcare norms (sector average: 19.13%) and against GRPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -1134.97%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Graphite Bio, and consider following GRPH for alerts when major investors trade the stock.